Sagent Pharmaceuticals Announces Launch of Octreotide Acetate Injection
December 23, 2013 at 14:31 PM EST
Sagent Pharmaceuticals (Nasdaq: SGNT ) today announced the launch of Octreotide Acetate Injection, a Somatostatin Analog, in five vial presentations. According to IMS, for the 12 months ending October 2013, the US market for Octreotide Acetate Injection approximated $45 million. As with all products in Sagent's portfolio, Octreotide features